Abstract
The aim of the study was to evaluate the clinical efficacy, safety, and tolerability of a fixed-dose combination of donepezil and memantine (Mioreol) in patients with Alzheimer's disease (AD) and AD with cerebrovascular pathology. 497 patients with moderate to severe dementia, average age 75.4+6.81 years, received Mioreol (donepezil 10 mg+memantine 20 mg). Treatment efficacy was assessed using the MMSE, clock drawing, Sandoz Clinical Geriatric Scale, and Clinical Global Impressions after 3 months of therapy. All adverse events during treatment were recorded. The transition to Mioreol was accompanied by a reliable improvement in cognitive functions, emotional-behavioral indicators and neuropsychiatric status in general. Mioreol demonstrated clinical efficacy, safety and good tolerability in patients with AD and AD with cerebrovascular pathology with moderate to severe dementia syndrome.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call